EDISON, N.J., Nov. 7, 2016 /PRNewswire/ -- ContraVir
Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company
focused on the development and commercialization of targeted
antiviral therapies, today announced that it will present a poster
at The Liver Meeting® 2016 held by the American
Association for the Study of Liver Diseases (AASLD), taking place
November 11-15, 2016, in Boston.
The poster, titled, "Pharmacokinetics, Safety and Antiviral
Activity of CMX157, a Novel Prodrug of Tenofovir, Administered as
Ascending Multiple Doses to Healthy Volunteers and HBV-Infected
Subjects," will provide an overview of recent clinical data
supporting CMX157, the company's drug in development for hepatitis
B virus (HBV).
Conference Details:
Event:
|
|
The Liver Meeting
2016
|
Date:
|
|
Monday, November 14,
2016
|
Session:
|
|
Poster Session IV,
"Hepatitis B: Treatment"
|
Poster
#:
|
|
1886
|
Location:
|
|
John B. Haynes
Veterans Memorial Convention Center; Boston
|
|
|
|
About ContraVir Pharmaceuticals
ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted antiviral therapies with a specific
focus on developing a potentially curative therapy for hepatitis B
virus (HBV). The Company is developing two novel anti-HBV compounds
with complementary mechanisms of action: CMX157, a highly potent
analog of the successful antiviral drug tenofovir currently in a
Phase 2a clinical trial in HBV patients; and CRV431, a next
generation cyclophilin inhibitor with a unique structure that
increases its potency and selective index against HBV. ContraVir is
also developing FV-100, an orally available nucleoside analogue
prodrug for the treatment of herpes zoster, or shingles, in a Phase
3 clinical trial. In addition to direct antiviral activity,
FV-100 previously demonstrated the potential to reduce the
incidence of debilitating shingles-associated pain known as
post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For
more information visit www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664
Claire LaCagnina (media)
clacagnina@tiberend.com; (212) 375-2686
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/contravir-to-present-at-aaslds-the-liver-meeting-2016-300358109.html
SOURCE ContraVir Pharmaceuticals, Inc.